FDA approval News
Most Popular FDA approval Story
Alexza's Adasuve slapped with delayed FDA review
The FDA slammed Alexza Pharmaceuticals ($ALXA) with another setback this week in its drive to bring the antipsychotic drug Adasuve to market. Regulators are extending by three months their review of Read more >>
Latest Headlines
- January 24, 2012
- June 22, 2011
- May 4, 2010
- April 27, 2010
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
